Usefulness of 18F-FDG PET/CT in cutaneous melanoma patients with negative sentinel lymph nodes and high clark levels Sentinel lenf nodu negatif yüksek clark seviyeli kutanöz melanom hastalarında18F-FDG PET/BT’nin değeri
Molecular Imaging and Radionuclide Therapy, cilt.27, sa.2, ss.66-72, 2018 (Scopus, TRDizin)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 27 Sayı: 2
- Basım Tarihi: 2018
- Doi Numarası: 10.4274/mirt.70783
- Dergi Adı: Molecular Imaging and Radionuclide Therapy
- Derginin Tarandığı İndeksler: Scopus, TR DİZİN (ULAKBİM)
- Sayfa Sayıları: ss.66-72
- Anahtar Kelimeler: F-18-FDG, melanoma, sentinel lymph node biopsy
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Objective: We investigated the utility of PET/CT in cutaneous melanoma (CM) patients with pathological negative sentinel lymph nodes (SLN), within the first year. Methods: The results of PET/CTs and SLN biopsy (SLNB) in 65 patients (39 male and 26 female, mean age 53.8) with a PET/CT in the first postoperative year were evaluated. Within this cohort, the utility of early PET/CT imaging was assessed in patients with negative SLNB. McNemar test was used to compare PET/CT findings with SLNB results. Results: Out of 43 patients with pathologically positive SLNs, 23 patients (53.5%) had positive and 20 patients (46.5%) had negative findings on PET/CT within the first postoperative year. On the other hand, PET/CT results of 22 patients with negative SLNBs were found to be negative in 19 patients (86.4%) and positive in 3 patients (13.6%). For the patients with negative SLNB results, the detection rate of distant metastasis with PET/CT was significantly lower (p<0.001) than that in patients with positive SLNBs. Conclusion: Our results showed that 18F-FDG PET/CT will most likely (86.4%) be negative during the first postoperative year in patients with a negative SLNB. Therefore, it is concluded that this modality would not provide any significant clinical contribution within this time frame.